Jonathan Cohen, Director of Clinical Research at Sharett Institute of Oncology of Hadassah Medical Center, shared on LinkedIn:

“I had the opportunity to discuss various topics in hepatocellular carcinoma at the annual meeting of the Israeli Oncology Society (ISCORT).

Some points of discussion:

• Should all HCC patients undergo biopsies?
  – This will probably become SOC soon with ADC’s and other biomarker-driven therapies; but not yet.
• When should systemic therapies be introduced?
  – Adjuvant data is not ripe, but I would strongly consider when loco-regional disease recurs. Survival data will be crucial.
  – Neoadjuvant treatment makes sense. Awaiting data.
  – Downstaging with ICI before liver transplant – some ongoing single institution studies. Risk of rejection? Loss of systemic protection due to immune-suppression? vs. potential for cure?
• How should increased LFT’s be handled in HCC patients receiving ICI?
  – Don’t rush to label as irAE.
• What’s going on in the clinical research arena for HCC?
  – ADC’s
  – Immune-cell engagers
  – Novel combinations
  – Personalized neoantigen vaccine.”

View additional information.
Source: Jonathan Cohen/LinkedIn